Karyopharm Therapeutics Inc. (NASDAQ:KPTI) does about 2.70M shares in volume on a normal day but saw 1934301 shares change hands in Monday trading. The company now has a market cap of 261.46M USD. Its current market price is $3.25, marking a decrease of -3.56% compared to the previous close of $3.37. The 52 week high reached by this stock is $14.73 whilst the lowest price level in 52 weeks is $2.45. The script in recent trading has seen the stock touch a high of $3.40 and a low of $3.23.
Karyopharm Therapeutics Inc. (KPTI) has a 20-day trading average at $3.09 and the current price is -77.94% off the 52-week high compared with 32.65% distance from its 52-week low. The 50-day simple moving average of the closing price is $4.01 and its 200-day simple moving average is $5.05. If we look at the stock’s price movements over the week, volatility stands at 8.83%, which increases to 11.22% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 47.00 to suggest the stock is neutral.
The consensus objective for the share price is $8.80, suggesting that the stock has a potential upside of 63.07% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on January 19, 2023 when Piper Sandler initiated the stock to “Overweight” and issued a price target of $8. RBC Capital Mkts upgraded the stock to “Outperform” from Sector Perform on November 04, 2022 at a price target of $7-$10. JP Morgan upgraded its price target at $8.
The current price level is 5.71%, -19.74%, and -35.90% away from its SMA20, SMA50, and SMA200 respectively, with the KPTI price moving above the 50-day SMA on January 23. Karyopharm Therapeutics Inc. (KPTI) stock is down -1.52% over the week and 7.62% over the past month. Its price is -4.41% year-to-date and -57.96% over the past year.
The stock last released its quarterly earnings report for quarter ended 9/29/2022, with the company’s earnings per share (EPS) of -$0.45 above consensus estimates by $0.12. KPTI’s earnings per share are forecast to shrink by -17.60% this year and 32.00% over next year. Expected sales for next quarter are $38.89 million, which analysts say will come at $159.38 million for the current fiscal year and next year at $169.98 million. In addition, estimates put the company’s current quarterly revenue at an average of $35.85 million.
To reach the target analysts have set, the stock logically needs to grow 63.07 percent from here.
Outstanding shares total 80.21M with insiders holding 8.67% of the shares and institutional holders owning 102.09% of the company’s common stock. The company has a return on investment of -44.30% and return on equity of 84.00%. The beta has a value of -0.04. Price to sales ratio is 1.05.
According to a U.S. Securities and Exchange Commission filing, SPDR S&P Biotech ETF has added its position in Karyopharm Therapeutics Inc. (KPTI) to 6,835,912 shares, mirroring a recent increase by 0.41%. SPDR S&P Biotech ETF added 27632.0 shares of Karyopharm Therapeutics Inc. common stock bringing its total worth to about $23.24 million at the end of recent close, SEC documents show. iShares Russell 2000 ETF cut their holdings by -1.03% in the company over the course of the most recent quarter. It now holds a 2.15% position in Karyopharm Therapeutics Inc. thanks to 1.75 million shares amounting to $5.93 million.